ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "axial spondyloarthritis"

  • Abstract Number: 2779 • 2019 ACR/ARP Annual Meeting

    Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors

    Alexandre Sepriano1, Sofia Ramiro 2, Stephanie Wichuk 3, Praveena Chiowchanwisawakit 4, Terrie MacCosham 3, Joel Paschke 5, Désirée van der Heijde 1, Robert B.M. Landewé 6 and Walter Maksymowych 7, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 3University of Alberta, Edmonton, Canada, 4Mahidol University, Bangkok, Thailand, 5CARE Arthritis, Edmonton, Canada, 6Amsterdam University Medical Center, Amsterdam, Netherlands, 7University of Alberta and CARE Arthritis, Edmonton, Canada

    Background/Purpose: The association between disease activity and spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) has been previously shown in a cohort of patients (pts)…
  • Abstract Number: 577 • 2019 ACR/ARP Annual Meeting

    Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients

    Ann-Sophie De Craemer1, Thomas Renson 1, Liselotte Deroo 1, Manouk de Hooge 1, Philippe Carron 1, Filip Van den Bosch 1 and Dirk Elewaut 1, 1Ghent University Hospital, Ghent, Belgium

    Background/Purpose: Disease activity in axial spondyloarthritis (axSpA) is often quantified by the Ankylosing Spondylitis Disease Activity Score (ASDAS), a composite index which combines 4 patient…
  • Abstract Number: 608 • 2019 ACR/ARP Annual Meeting

    Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls

    Freke Wink1, Thomas Diemel 2, Suzanne Arends 2 and Anneke Spoorenberg 2, 1Medical Center Leeuwarden, Leeuwarden, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Enthesitis is one of the features of ankylosing spondylitis (AS). High prevalence of structural and inflammatory ultrasound lesions of peripheral entheses are found in…
  • Abstract Number: 856 • 2019 ACR/ARP Annual Meeting

    MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?

    Ulrich Weber1, Anne Grethe Jurik 2, Anna Zejden 2, Ejnar Larsen 3, Steen Hylgaard Jørgensen 4, Kaspar Rufibach 5, Christian Schioldan 6 and Søren Schmidt-Olsen 7, 1Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, 2Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, 3Department of Radiology, North Denmark Regional Hospital, Hjørring, Denmark, 4Center for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark, 5Division of Biostatistics, F. Hoffmann-La Roche, Basel, Switzerland, 6Department of Physiotherapy, Clinic Benefit, Frederikshavn, Denmark, 7Department of Rheumatology and Sports Medicine, North Denmark Regional Hospital, Hjørring, Denmark

    Background/Purpose: Low grade bone marrow edema (BME) on magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ) is challenging the discrimination between patients with early…
  • Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting

    Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study

    René-Marc Flipo 1, Florence Tubach 2, Jean Ouaniche 3, Philippe Goupille4, Eric Lespessailles 5, Najat Gouyette 6, Naoual Harid 7, Jean-Marie Fayette 8, Philippe Bertin 9 and Bruno Fautrel 10, 1Roger Salengro University-Hospital, Lille , France, Lille, France, 2Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, 3Private Practice , Toulon, France, Toulon, France, 4Tours University-Hospital, Tours, France, Tours, France, 5Orléans Regional Hospitals, Orléans ,France, Orléans, France, 6MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, 7MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, 8ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, 9Limoges University-Hospital , Limoges, France, Limoges, France, 10Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France

    Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…
  • Abstract Number: 1778 • 2019 ACR/ARP Annual Meeting

    Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis

    Sungsin Jo1, Young Lim Lee 1, Tae-Han Lee 1, Ye-Soo Park 2 and Tae-Hwan Kim 1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2Department of Orthopedic Surgery, Hanyang University Medical Center, Guri Hospital,, Guri, Republic of Korea

    Background/Purpose: Enthesitis is characterized by inflammation at the interface where tendon or ligament attaches to the bone and is a representative symptom of ankylosing spondylitis(AS).…
  • Abstract Number: 579 • 2019 ACR/ARP Annual Meeting

    Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?

    Imke Redeker1, Johanna Callhoff 2, Falk Hoffmann 3, Hildrun Haibel 4, Joachim Sieper 4, Angela Zink 5 and Denis Poddubnyy 6, 1Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Carl von Ossietzky University, Oldenburg, Germany, 4Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 5German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, 6Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany

    Background/Purpose: Uveitis, psoriasis and inflammatory bowel disease (IBD) are common in axial spondyloarthritis (axSpA) but data on their impact on activity of musculoskeletal manifestations and…
  • Abstract Number: 609 • 2019 ACR/ARP Annual Meeting

    Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort

    Clementina López-Medina1, Anna Moltó 2, Pascal Claudepierre 3 and Maxime Dougados 4, 1Cochin Hospital, Rheumatology Department, Paris, France, 2Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 3Rheumatology, CHU Henri Mondor Créteil, Paris, France, 4Cochin Hospital, Paris, France

    Background/Purpose: There is still a debate concerning the concept of non-radiographic (nr-axSpA) axial Spondyloarthritis (e.g. to consider it as a distinct entity from r-axSpA (Ankylosing…
  • Abstract Number: 935 • 2019 ACR/ARP Annual Meeting

    Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study

    Irene van der Horst-Bruinsma1, Rianne van Bentum 1, Frank D. Verbraak 1, Thomas Rath 2, James T. Rosenbaum 3, Maria Misterska-Skóra 4, Bengt Hoepken 5, Oscar Irvin-Sellers 6, Brenda VanLunen 7, Lars Bauer 5 and Martin Rudwaleit 8, 1Amsterdam University Medical Center, Amsterdam, Netherlands, 2St Franziskus-Hospital, Münster, Germany, 3Devers Eye Institute and Oregon Health & Science University, Portland, OR, 4Wrocław Medical University, Wrocław, Poland, 5UCB Pharma, Monheim am Rhein, Germany, 6UCB Pharma, Slough, UK, Slough, United Kingdom, 7UCB Pharma, Raleigh, NC, 8Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany

    Background/Purpose: Acute anterior uveitis (AAU), inflammation of the anterior uveal tract, is the most common extraarticular manifestation in patients (pts) with axial spondyloarthritis (axSpA), reported…
  • Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting

    Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?

    Santiago Rodrigues-Manica1, Alexandre Sepriano 2, Fernando Pimentel-Santos 1, Nélia Gouveia 3, Anabela Barcelos 4, Jaime Branco 1, Miguel Bernardes 5, Raquel Miriam-Ferreira 5, Elsa Vieira-Sousa 6, Sofia Barreira 6, Filipe Vinagre 7, Raquel Roque 7, Helena Santos 8, Nathalie Madeira 8, João Rovisco 9, Alexandra Daniel 9 and Sofia Ramiro 10, 1CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, 2Leiden University Medical Center, Leiden, Netherlands, 3CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, 4Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, 5Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, 6Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 7Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, 8Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 9Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, 10Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands

    Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…
  • Abstract Number: 1820 • 2019 ACR/ARP Annual Meeting

    Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient

    Uta Kiltz1, Eerik Ahomaa 2, Björn Bühring 3, Xenofon Baraliakos 4 and Jürgen Braun 5, 1Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 2Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Bochum, Germany, 3Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

    Background/Purpose: Physical function in axial spondyloarthritis (axSpA) usually assessed by the BASFI questionnaire is an established core domain of that disease. There is evidence that…
  • Abstract Number: 580 • 2019 ACR/ARP Annual Meeting

    Association of Comorbidities with Disease Activity and Functional Impairment in Axial Spondyloarthritis: Results from a Nationwide Population-Based Study

    Imke Redeker1, Johanna Callhoff 2, Falk Hoffmann 3, Hildrun Haibel 4, Joachim Sieper 4, Angela Zink 5 and Denis Poddubnyy 6, 1Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Carl von Ossietzky University, Oldenburg, Germany, 4Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 5German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, 6Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany

    Background/Purpose: Data on the prevalence of comorbidities and their association with disease activity and functional impairment in axial spondyloarthritis (axSpA) are scarce. The aim of…
  • Abstract Number: 612 • 2019 ACR/ARP Annual Meeting

    Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients

    Rianne van Bentum1, Sebastian Ibáñez Vodnizza 2, Francisca Valenzuela Aldridge 2, Maria Paz Poblete 3, Salima van weely 4, Marieke ter Wee 1, Omar Valenzuela 5 and Irene van der Horst-Bruinsma 1, 1Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, 2Rheumatology dpt., Clínica Alemana - UDD Medicine faculty, Santiago, Chile, 3Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, 4Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, 5Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile

    Background/Purpose: In axial spondyloarthritis (axSpA), preservation of physical functioning is an important treatment goal and is usually assessed with the patient-reported BASFI questionnaire. The Ankylosing…
  • Abstract Number: 936 • 2019 ACR/ARP Annual Meeting

    Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes

    Jonathan Kay1, Lianne Gensler 2, Atul Deodhar 3, Walter P. Maksymowych 4, Nigil Haroon 5, Simone Auteri 6, Natasha de Peyrecave 7, Thomas Kumke 8, Bengt Hoepken 9, Lars Bauer 9 and Martin Rudwaleit 10, 1UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 2University San Francisco California, San Francisco, CA, 3Oregon Health & Science University, Portland, OR, 4University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, 5Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, 6UCB Pharma, Brussels, Belgium, 7UCB Pharma, Slough, United Kingdom, 8UCB Pharma, Monheim, Germany, 9UCB Pharma, Monheim am Rhein, Germany, 10Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany

    Background/Purpose: Patients (pts) with axial spondyloarthritis (axSpA) often experience delayed diagnosis, which can lead to treatment delay. However, there are indications that earlier treatment with…
  • Abstract Number: 1501 • 2019 ACR/ARP Annual Meeting

    Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors

    Maxime Dougados1, Joachim Sieper 2, Xenofon Baraliakos 3, Filip Van den Bosch 4, Walter P. Maksymowych 5, Joerg Ermann 6, Xiaoqi Li 7, Gaia Gallo 8, Hilde Carlier 7 and Lianne Gensler 9, 1Hôpital Cochin, Paris, France, 2Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 3Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 4Ghent University Hospital, Ghent, Belgium, 5University of Alberta, Edmonton, AB, Canada, 6Brigham and Women's Hospital, Boston, 7Eli Lilly and Company, Indianapolis, 8Eli Lilly and Company, Indianapolis, IN, 9University San Francisco California, San Francisco, CA

    Background/Purpose: Week 16 results from COAST-W (NCT02696798) showed that ixekizumab (IXE) was superior to placebo (PBO) in improving the signs and symptoms of active radiographic…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology